Arkema S.A.

DB:V1S Stock Report

Market Cap: €5.8b

Arkema Valuation

Is V1S undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of V1S when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: V1S (€76.7) is trading below our estimate of fair value (€222.18)

Significantly Below Fair Value: V1S is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for V1S?

Key metric: As V1S is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for V1S. This is calculated by dividing V1S's market cap by their current earnings.
What is V1S's PE Ratio?
PE Ratio16.9x
Earnings€346.00m
Market Cap€5.85b

Price to Earnings Ratio vs Peers

How does V1S's PE Ratio compare to its peers?

The above table shows the PE ratio for V1S vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average28.7x
EVK Evonik Industries
36.2x33.1%€8.3b
WCH Wacker Chemie
29.5x38.0%€3.7b
SY1 Symrise
37.2x13.1%€14.6b
ACT AlzChem Group
11.8x12.6%€592.3m
V1S Arkema
16.9x20.6%€5.8b

Price-To-Earnings vs Peers: V1S is good value based on its Price-To-Earnings Ratio (16.9x) compared to the peer average (28.7x).

Price to Earnings Ratio vs Industry

How does V1S's PE Ratio compare vs other companies in the European Chemicals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
V1S 16.9xIndustry Avg. 17.7xNo. of Companies11PE01224364860+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: V1S is good value based on its Price-To-Earnings Ratio (16.9x) compared to the European Chemicals industry average (17.7x).

Price to Earnings Ratio vs Fair Ratio

What is V1S's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

V1S PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio16.9x
Fair PE Ratio18.3x

Price-To-Earnings vs Fair Ratio: V1S is good value based on its Price-To-Earnings Ratio (16.9x) compared to the estimated Fair Price-To-Earnings Ratio (18.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst V1S forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€76.70
€106.97
+39.5%
9.7%€125.00€89.00n/a17
Nov ’25€80.35
€107.62
+33.9%
9.5%€125.00€89.00n/a17
Oct ’25€85.90
€107.85
+25.6%
9.9%€125.00€89.00n/a17
Sep ’25€83.90
€109.50
+30.5%
9.9%€127.00€92.00n/a17
Aug ’25€84.50
€110.44
+30.7%
10.3%€127.00€92.00n/a17
Jul ’25€83.40
€111.47
+33.7%
9.3%€127.00€92.00n/a17
Jun ’25€94.15
€112.00
+19.0%
8.3%€127.00€92.00n/a16
May ’25€96.50
€110.00
+14.0%
8.4%€127.00€90.00n/a16
Apr ’25€97.28
€110.44
+13.5%
9.2%€134.00€90.00n/a16
Mar ’25€94.08
€111.88
+18.9%
8.7%€134.00€90.00n/a16
Feb ’25€100.75
€112.06
+11.2%
8.8%€134.00€90.00n/a16
Jan ’25€102.25
€111.73
+9.3%
7.7%€123.00€90.00n/a15
Dec ’24€93.40
€110.07
+17.8%
8.4%€123.00€90.00n/a15
Nov ’24€87.68
€110.40
+25.9%
8.5%€123.00€90.00€80.3515
Oct ’24€92.96
€109.60
+17.9%
8.6%€125.00€90.00€85.9015
Sep ’24€97.46
€107.25
+10.0%
11.2%€125.00€85.00€83.9016
Aug ’24€96.06
€107.00
+11.4%
11.4%€125.00€85.00€84.5016
Jul ’24€86.20
€105.68
+22.6%
11.4%€123.00€82.50€83.4017
Jun ’24€82.10
€105.19
+28.1%
12.7%€130.00€82.50€94.1518
May ’24€89.30
€106.97
+19.8%
14.8%€142.00€82.50€96.5018
Apr ’24€90.56
€107.42
+18.6%
14.7%€142.00€82.50€97.2818
Mar ’24€96.10
€103.97
+8.2%
15.9%€142.00€80.00€94.0818
Feb ’24€92.54
€102.31
+10.6%
15.6%€134.00€79.00€100.7518
Jan ’24€84.78
€102.92
+21.4%
15.6%€134.00€78.00€102.2518
Dec ’23€85.50
€103.47
+21.0%
15.7%€134.00€78.00€93.4018
Nov ’23€81.54
€103.97
+27.5%
18.1%€140.00€72.00€87.6818

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Tokuyama

JP¥188.8b

Produces and sells various chemical products in Japan.

TBT

JP¥15.70

7D

-4.8%

1Y

10.6%

Minerals Technologies

US$2.6b

Develops, produces, and markets various mineral, mineral-based, and related systems and services.

MNK

US$77.00

7D

-1.3%

1Y

35.1%

Mitsubishi Chemical Group

JP¥1.2t

Provides performance products, chemicals, industrial gases, health care products, and other products in Japan and internationally.

M3C

JP¥4.96

7D

1.1%

1Y

-10.4%